XML 48 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2

Long-Term Investments (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2024

Dec. 31, 2023

Long-Term Investments [Abstract]

Schedule of Ownership Percentages of Each Investee

The ownership percentages of each investee are listed as follows:

		Ownership percentage
		March 31,				December 31,				Accounting
Name of related party		2024				2023				treatments
Braingenesis Biotechnology Co., Ltd.			0.17	%			0.17	%		Cost Method
Genepharm Biotech Corporation			0.67	%			0.67	%		Cost Method
BioHopeKing Corporation			5.90	%			5.90	%		Cost Method
BioFirst Corporation			18.68	%			18.68	%		Equity Method
Rgene Corporation			26.65	%			26.65	%		Equity Method

The ownership percentages of each investee are listed as follows:

		Ownership percentage
		December 31,				December 31,				Accounting
Name of related party		2023				2022				treatments
Braingenesis Biotechnology Co., Ltd.			0.17	%			0.17	%		Cost Method
Genepharm Biotech Corporation			0.67	%			0.67	%		Cost Method
BioHopeKing Corporation			5.90	%			5.90	%		Cost Method
BioFirst Corporation			18.68	%			15.51	%		Equity Method
Rgene Corporation			26.65	%			26.65	%		Equity Method

Schedule of Extent the Investee Relies

The extent the investee relies on the company for its business are summarized as follows:

Name of related party		The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.		No specific business relationship
Genepharm Biotech Corporation		No specific business relationship
BioHopeKing Corporation		Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation		Loaned from investee and provides research and development support service
Rgene Corporation		Collaborating with the Company to develop and commercialize drugs

The extent the investee relies on the company for its business are summarized as follows:

Name of related party		The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.		No specific business relationship
Genepharm Biotech Corporation		No specific business relationship
BioHopeKing Corporation		Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation		Loaned from the investee and provides research and development support service
Rgene Corporation		Collaborating with the Company to develop and commercialize drugs

Schedule of Long-Term Investment

Long-term investment mainly consists of the following:

		March 31, 2024				December 31, 2023
		(Unaudited)
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.		$	6,904			$	7,213
Genepharm Biotech Corporation			21,078				22,021
BioHopeKing Corporation			782,995				818,018
Sub total			810,977				847,252
Equity Method Investments, net
BioFirst Corporation			1,663,537				1,680,488
Rgene Corporation			-				-
Total		$	2,474,514			$	2,527,740

Long-term investment mainly consists of the following:

		December 31, 2023				December 31, 2022
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.		$	7,213			$	7,169
Genepharm Biotech Corporation			22,021				21,887
BioHopeKing Corporation			818,018				813,014
Subtotal			847,252				842,070
Equity Method Investments, net
BioFirst Corporation(a)			1,680,488				-
Rgene Corporation(b)			-				-
Total		$	2,527,740			$	842,070

Schedule of Balance Sheet

Balance Sheets

		March 31, 2024				December 31, 2023
		(Unaudited)
Current Assets		$	1,439,444			$	1,451,877
Non-current Assets			651,560				686,206
Current Liabilities			2,663,111				2,286,058
Non-current Liabilities			101,908				347,193
Stockholders’ Equity (Deficit)			(674,015	)			(495,168	)

		March 31, 2024				December 31, 2023
		(Unaudited)
Current Assets		$	49,496			$	50,538
Non-current Assets			238,193				250,716
Current Liabilities			2,535,581				2,591,960
Non-current Liabilities			1,194				811
Shareholders’ Deficit			(2,249,086	)			(2,291,517	)

Balance Sheet

		December 31, 2023				December 31, 2022
Current Assets		$	1,451,877			$	1,543,151
Non-current Assets			686,206				739,472
Current Liabilities			2,286,058				2,663,051
Non-current Liabilities			347,193				103,447
Stockholders’ Equity			(495,168	)			(483,874	)

		December 31, 2023				December 31, 2022
Current Assets		$	50,538			$	68,302
Non-current Assets			250,716				303,893
Current Liabilities			2,591,960				2,478,868
Non-current Liabilities			811				2,441
Shareholders’ Deficit			(2,291,517	)			(2,481,309	)

Schedule of Statement of Operation

Statement of Operations

		Three months Ended March 31,
		2024				2023
		(Unaudited)
Net sales		$	363			$	-
Gross profit			220				-
Net loss			(203,077	)			(406,233	)
Share of losses from investments accounted for using the equity method			-				-

		Three months Ended March 31,
		2024				2023
		(Unaudited)
Net sales		$	-			$	-
Gross Profit			-				-
Net loss			(56,567	)			(81,842	)
Share of loss from investments accounted for using the equity method			-				-

Statement of operation

		Year Ended December 31,
		2023				2022
Net sales		$	734			$	30,162
Gross profit			289				8,239
Net loss			(1,194,797	)			(1,274,539	)
Share of losses from investments accounted for using the equity method			(221,888	)			-

		Year Ended December 31,
		2023				2022
Net sales		$	-			$	-
Gross Profit			-				-
Net loss			(291,522	)			(1,550,123	)
Share of loss from investments accounted for using the equity method			-				-

Schedule of Loss on Investment in Equity Securities

The components of losses on equity investments for each period were as follows:

		Three months Ended March 31,
		2024				2023
		(Unaudited)
Share of equity method investee losses		$	-			$	-

The components of loss on investment in equity securities for each period were as follows:

		Year Ended December 31,
		2023				2022
Share of equity method investee losses		$	(221,888	)		$	-

X

- Definition

Tabular disclosure of extent the investee relies.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvc_ScheduleOfLongTermInvestmentTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 04
-Paragraph a
-Publisher SEC

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix:	srt_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 04
-Paragraph a
-Publisher SEC

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_LongTermInvestmentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration